Navigation Links
Potent possibilities for parasite attack

A comparison of three parasite species that cause Leishmaniasis has identified a small number of genes, many new to biology, that will provide a framework to target the search for new treatments. Leishmaniasis is a devastating disease that affects about two million people each year and threatens one-fifth of the world's population and new treatments are desperately needed.

In their report in Nature Genetics, published online on Sunday 17 June 2007, the researchers compared the genomes of L. infantum and L. braziliensis, which cause life-threatening visceral and disfiguring mucocutaneous leishmaniasis, respectively, with the sequence they produced in 2005 for L. major, which causes a less severe, cutaneous form of the disease. Despite the major differences in disease type, only 200 out of more than 8000 genes present in each genome were found to be differentially distributed between the three species. This exceptionally small variation in gene content has given new insights into those processes that may determine disease severity in humans.

"Identifying factors that allow three closely related organisms to cause vastly different clinical outcomes is a major quest for researchers and in this study we have narrowed the search to a number that can be realistically studied," commented Dr Matt Berriman, senior author on the paper, from the Wellcome Trust Sanger Institute.

The researchers found only five genes in the L. major genome for which no trace could be found in the other two species. By contrast, in Plasmodium, which causes malaria, about 20% of genes differ between related species.

"Clearly there must have been considerable evolutionary pressure over time to maintain the structure and sequence of the Leishmania genomes - the degree of similarity between these species was unexpected," explained Professor Deborah Smith, collaborator on this project at the University of York. "Perhaps only a few parasite genes are important i
'"/>

Source:Wellcome Trust Sanger Institute


Page: 1 2 3

Related biology news :

1. Novel Enzyme Shows Potential As An Anti-HIV Target
2. Potential Cure for Lymphoma in HIV patients
3. Potential treatments for neurofibromatosis
4. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
5. Potential Drug Target For Treating Cocaine Abuse Found
6. Potential vaccine developed for deadly leishmaniasis disease
7. Potential heart benefit found in stem cells
8. New possibilities for flu antiviral and vaccine research emerge from Spanish flu virus
9. New possibilities to fight pests with biological means
10. Three-dimensional, miniature endoscope opens new diagnostic possibilities
11. Heart failure: Intervention possibilities from imaging programmed cell loss
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Potent possibilities for parasite attack

(Date:4/27/2015)... 2015 Profile Solutions, Inc. (OTC: PSIQ), a ... is pleased to announce that Dr Gerry Bedore ... member of its scientific advisory board. ... thought leader in technology-enhanced learning models. He was a ... published studies and books focused on online student success ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... that the effects of prion disease could be reversed ... findings support developing early treatments that aim to reduce ... with prion disease. Also, they said that their findings ... way: by analyzing their cognitive effects in prion-infected mice. ...
... autopsy data provide the strongest evidence yet that sudden infant ... a concrete biological basis. In the November 1 issue of ... brainstem ?a part of the brain that regulates breathing, blood ... SIDS. , SIDS is the leading cause of death ...
... Jude Children's Research Hospital have demonstrated in a mouse model ... that not only greatly reduces the size of the tumor, ... standard chemotherapy. The treatment also appears to be suitable for ... is simple enough for widespread use even in countries with ...
Cached Biology News:Prion disease treatable if caught early 2A potential biological cause for sudden infant death syndrome 2A potential biological cause for sudden infant death syndrome 3St. Jude announces breakthrough in eye cancer treatment 2St. Jude announces breakthrough in eye cancer treatment 3St. Jude announces breakthrough in eye cancer treatment 4
(Date:4/27/2015)... 2015  For about a century, a known ... to utilize and catabolize glucose at a high ... called the ,Warburg phenomenon", that is an increased ... presence, leading to enhanced lactate generation. Even under ... glucose fermentation. A variety of such abnormalities have ...
(Date:4/27/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the year ended December 31, 2014. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... not provide the outcome management and investors had ... iCo Therapeutics", said Andrew Rae , President ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 /PRNewswire/ ... para un nuevo receptor utilizando tecnología de descubrimiento de ... cubierta en el tratamiento de millones de pacientes con ... hoy que ha recibido una patente en Europa titulada ... descubrimiento de Molecular Health de que EPHB4 es un ...
(Date:4/27/2015)... Dr. Robert Hanzlik, whose groundbreaking research into ... for advancing the creation of safer pharmaceuticals, will be ... , the second-largest private, nonprofit university in California. , ... at the University of Kansas School of Pharmacy who ... 5 p.m. and takes place at National University’s Torrey ...
Breaking Biology Technology:Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3
... , , PRINCETON, N.J., July 24 ... companies from around the world who gather at InformexUSA 2010 will ... past, allowing them to connect more precisely with others in their ... The show opens February 16, 2010 in San Francisco, with a ...
... , SILVER SPRING, Md., July 24 ... that it will release its 2009 second quarter financial results ... , United Therapeutics Corporation will host ... a.m. Eastern Time. The teleconference is accessible by dialing ...
... ... offers Fetal Bovine Serum (FBS) originating from abattoirs located in the US, ... treatments such as heat inactivation, dialysis, or gamma irradiation are available as ... FBS for embryonic stem cell research. Each FBS order includes a ...
Cached Biology Technology:Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 2Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 3Spectrum Announces Fetal Bovine Serum Product Line 2
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
Ubiquitin-conjugating enzyme E2N...
Biology Products: